| Antigen: |
Integrin αVβ-3 (CD51/61; Osteoclast Functional Antigen) |
| Relevance: |
Integrins are heterodimeric
cell surface receptors composed of a and ß subunits,
which mediate cell-cell and cell-extracellular matrix
attachments. Aberrant integrin expression has been found
in many epithelial tumours. Changes in integrin expression
have been shown to be important for the growth and early
metastatic capacity of melanoma cells. Integrin aVß3
is the predominant integrin of osteoclasts (bone resorbing
cells) and is upregulated in malignant melanoma. Integrin
aVß3
binds to a range of ECM proteins (e.g. vitronectin,
fibrinogen, fibronectin) via an Arg-Gly-Asp (RGD) motif.
23C6 may be useful for bone resorption modulation, osteoclast
identification, receptor purification, malignant melanoma
identification and treatment. |
| Clone: |
23C6 |
| Subclass: |
IgG1 |
| Applications: |
Immunohistochemistry (Frozen, Acetone Fixed), FACS, Neutralising, Immunoprecipitation |
| Immunogen: |
A cell suspension containing osteoclasts from osteoclastomas. |
| Reactivity: |
Human |
| Species raised in: |
Female Balb/c |
| Fusion partner: |
P3x63-Ag8.653 |
| Recommended growth conditions: |
DMEM 5% FCS |
| References: |
Horton
MA et al. 1985. Cancer Res. 45:5663-5669. 
Marshall
JF et al. 1995. J. Cell. Sci. 108:1227-38
|
| Notes: |
Positive control: Tonsil. 125/124 kDa (reduced), 150kDa (non-reduced) |
For further information about antibodies from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com
Please note that CRT supplies to distributors only. However, we are happy to direct researchers to the appropriate commercial party to obtain antibodies within our portfolio. Click here to view disclaimer information. |
